5-hydroxytryptamine- and dopamine-releasing effects of ring-substituted amphetamines on rat brain: A comparative study using in vivo microdialysis

European Neuropsychopharmacology

Volumn 24, Issue 8, 2014, Pages 1362-1370

  Matsumoto, T ^a,b   Maeno, Y ^b   Kato, H ^b   Seko Nakamura, Y ^b   Monma Ohtaki, J ^b   Ishiba, A ^a   Nagao, M ^c   Aoki, Y ^b  

^a AICHI PREFECTURAL UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

5 hydroxytryptamine; Amphetamines; Dopamine; Microdialysis; Monoamine oxidase

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4,5 TRIMETHOXYAMPHETAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4 METHYLTHIOAMPHETAMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE DERIVATIVE; DOPAMINE; METHAMPHETAMINE; P METHOXYAMPHETAMINE; P METHOXYMETHAMPHETAMINE; SEROTONIN; UNCLASSIFIED DRUG; 4-METHYLTHIOAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; CENTRAL STIMULANT AGENT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; COMPARATIVE STUDY; DIALYSATE; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; DRUG EFFECT; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; IC 50; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; ANIMAL; DRUG EFFECTS; EXTRACELLULAR FLUID; IC50; METABOLISM; TIME; WISTAR RAT;

AMPHETAMINES; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; EXTRACELLULAR FLUID; HYDROXYINDOLEACETIC ACID; INHIBITORY CONCENTRATION 50; MALE; MICRODIALYSIS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, WISTAR; SEROTONIN; TIME FACTORS;

EID: 84905004899     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.04.009     Document Type: Article

References (53)

1. Ask A.L., Fagervall I., Florvall L., Ross S.B., Ytterborn S. Selective inhibition of monoamine oxidase by p-aminosubstituted phenylalkylamines in catecholaminergic neurones. Neuropharmacology 1986, 25:33-40.
2. Bankson M.G., Cunningham K.A. Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 2002, 26:40-52.
3. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 1988, 149:159-163.
4. Battaglia G., Yeh S.Y., De Souza E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 1988, 29:269-274.
5. Baumann M.H., Clark R.D., Woolverton W.L., Wee S., Blough B.E., Rothman R.B. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J. Pharmacol. Exp. Ther. 2011, 337:218-225.
6. Fantegrossi W.E., Murnane K.S., Reissig C.J. The behavioral pharmacology of hallucinogens. Biochem. Pharmacol. 2008, 75:17-33.
7. Fletcher P.J., Sinyard J., Higgins G.A. The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists. Psychopharmacology 2006, 187:515-525.
8. Fuller R.W., Baker J.C., Perry K.W., Molloy B.B. Comparison of 4-chloro-, 4-bromo- and 4-fluoroamphetamine in rats: drug levels in brain and effects on brain serotonin metabolism. Neuropharmacology 1975, 14:739-746.
9. Fuller R.W., Perry K.W., Molloy B.B. Reversible and irreversible phases of serotonin depletion by 4-chloroamphetamine. Eur. J. Pharmacol. 1975, 33:119-124.
10. Fuller R.W., Perry K.W., Wong D.T., Molloy B.B. Effects of some homologues of 4-chloroamphetamine on brain serotonin metabolism. Neuropharmacology 1974, 13:609-614.
11. Gallardo-Godoy A., Fierro A., McLean T.H., Castillo M., Cassels B.K., Reyes-Parada M., Nichols D.E. Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J. Med. Chem. 2005, 48:2407-2419.
12. Gartside S.E., McQuade R., Sharp T. Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo. J. Pharmacol. Exp. Ther. 1996, 279:277-283.
13. Glennon R.A. Discriminative stimulus properties of hallucinogens and related designer drugs. NIDA. Res. Monogr. 1991, 116:25-44.
14. Glennon R.A. Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol. Biochem. Behav. 1999, 64:251-256.
15. Glennon R.A., Young R., Benington F., Morin R.D. Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane. J. Med. Chem. 1982, 25:1163-1168.
16. Glennon R.A., Young R., Dukat M., Cheng Y. Initial characterization of PMMA as a discriminative stimulus. Pharmacol. Biochem. Behav. 1997, 57:151-158.
17. Gough B., Ali S.F., Slikker W., Holson R.R. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol. Biochem. Behav. 1991, 39:619-623.
18. Gough B., Imam S.Z., Blough B., Slikker W., Ali S.F. Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann. N. Y. Acad. Sci. 2002, 965:410-420.
19. Green A.L., El Hait M.A. p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J. Pharm. Pharmacol. 1980, 32:262-266.
20. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 2003, 55:463-508.
21. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 1996, 66:243-249.
22. Gudelsky G.A., Yamamoto B.K. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol. Biochem. Behav. 2008, 90:198-207.
23. Huang M., Dai J., Meltzer H.Y. 5-HT(2A) and 5-HT(2C) receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT(2A) and 5-HT(2C) genetic mutant mice. Eur. J. Pharmacol. 2011, 652:40-45.
24. Jacob P., Shulgin A.T. Structure-activity relationships of the classic hallucinogens and their analogs. NIDA. Res. Monogr. 1994, 146:74-91.
25. Kankaanpaa A., Meririnne E., Lillsunde P., Seppala T. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol. Biochem. Behav. 1998, 59:1003-1009.
26. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., Yoshitake T. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 2011, 164:1949-1958.
27. Khorana N., Pullagurla M.R., Dukat M., Young R., Glennon R.A. Stimulus effects of three sulfur-containing psychoactive agents. Pharmacol. Biochem. Behav. 2004, 78:821-826.
28. Kita T., Wagner G.C., Nakashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J. Pharmacol. Sci. 2003, 92:178-195.
29. Koda L.Y., Gibb J.W. Adrenal and striatal tyrosine hydroxylase activity after methamphetamine. J. Pharmacol. Exp. Ther. 1973, 185:42-48.
30. Marek G.J., Aghajanian G.K. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J. Pharmacol. Exp. Ther. 1996, 278:1373-1382.
31. Marona-Lewicka D., Rhee G.S., Sprague J.E., Nichols D.E. Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur. J. Pharmacol. 1995, 287:105-113.
32. Mechan A.O., Esteban B., O'Shea E., Elliott J.M., Colado M.I., Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol. 2002, 135:170-180.
33. Nagai F., Nonaka R., Kamimura K.Satoh Hisashi The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 2007, 559:132-137.
34. Nash J.F., Nichols D.E. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. Eur. J. Pharmacol. 1991, 200:53-58.
35. Newton R.A., Phipps S.L., Flanigan T.P., Newberry N.R., Carey J.E., Kumar C., McDonald B., Chen C., Elliott J.M. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs. J. Neurochem. 1996, 67:2521-2531.
36. Nichols D.E. Hallucinogens. Pharmacol. Ther. 2004, 101:131-181.
37. Nichols D.E., Frescas S., Marona-Lewicka D., Huang X., Roth B.L., Gudelsky G.A., Nash J.F. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J. Med. Chem. 1994, 37:4346-4351.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney. second ed.
39. Poortman A.J., Lock E. Analytical profile of 4-methylthioamphetamine (4-MTA), a new street drug. Forensic. Sci. Int. 1999, 100:221-233.
40. Romero C.A., Bustamante D.A., Zapata-Torres G., Goiny M., Cassels B., Herrera-Marschitz M. Neurochemical and behavioural characterisation of alkoxyamphetamine derivatives in rats. Neurotox. Res. 2006, 10:11-22.
41. Sanders-Bush E., Bushing J.A., Sulser F. Long-term effects of p-chloroamphetamine and related drugs on central serotonergic mechanisms. J. Pharmacol. Exp. Ther. 1975, 192:33-41.
42. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 1987, 240:1-7.
43. Schmidt C.J., Taylor V.L. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem. Pharmacol. 1987, 36:4095-4102.
44. Schmidt C.J., Wu L., Lovenberg W. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur. J. Pharmacol. 1986, 124:175-178.
45. Scorza M.C., Carrau C., Silveira R., Zapata-Torres G., Cassels B.K., Reyes-Parada M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem. Pharmacol. 1997, 221:537-541.
46. Shulgin A.T., Sargent T., Naranjo C. Structure-activity relationships of one-ring psychotomimetics. Nature 1969, 221:537-541.
47. Shulgin A.T., Shulgin A. PiHKAL: A Chemical Love Story 1991, Transform Press, CA.
48. Steele T.D., Nichols D.E., Yim G.K. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem. Pharmacol. 1987, 36:2297-2303.
49. Stone D.M., Merchant K.M., Hanson G.R., Gibb J.W. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 1987, 26:1677-1683.
50. Stone D.M., Stahl D.C., Hanson G.R., Gibb J.W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol. 1986, 128:41-48.
51. Titeler M., Lyon R.A., Glennon R.A. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl.) 1988, 94:213-216.
52. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 1995, 273:1063-1070.
53. Young R., Glennon R.A. Discriminative stimulus properties of amphetamine and structurally related phenalkylamines. Med. Res. Rev. 1986, 6:99-130.